JAC Advance Access published online on April 10, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl136
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Infectious Diseases, San Martino Hospital and University of Genoa, Genoa, Italy
* To whom correspondence should be addressed. Objectives: Lopinavir/ritonavir is approved for treatment of HIV-infected children at a dosage regimen of 230/57.5 mg/m2 twice daily. However, once daily administration could increase convenience and patient adherence. Our study aimed at evaluating whether inhibitory concentrations are maintained in plasma following administration of lopinavir/ritonavir once daily. Patients and methods: Lopinavir/ritonavir was administered at the standard twice daily regimen to 21 HIV-infected children, as a component of their antiretroviral treatment. Following at least 1 month of administration, seven patients received a dose of 460/115 mg/m2 once daily for three consecutive days. After the third dose of once daily administration, blood samples were drawn at the following times: 0 (pre-dose), 1, 2 and 4 h following administration. The pre-dose (Cmin) and the peak (Cmax) concentrations were compared with the values obtained following twice daily administration in all the study patients. Results: Median (interquartile range) Cmin with the once daily regimen was 1.59 (0.77-6.85) mg/L versus 7.90 (5.45-9.77) mg/L with the twice daily regimen (P < 0.05). Cmin was considered inhibitory for wild-type virus (>1.0 mg/L) in four out of seven patients. Cmax did not differ significantly between the once daily and twice daily regimens. Conclusions: Our small pilot study suggests that lopinavir/ritonavir once daily may be a suitable regimen for antiretroviral-naive children. However, due to the high interindividual variability and low concentrations in some patients, therapeutic drug monitoring may be necessary to ensure that concentrations are adequate to inhibit viral replication. A formal clinical study of lopinavir/ritonavir once daily in treatment-naive children is warranted.
Received January 12, 2006
Revised March 13, 2006
Accepted March 20, 2006
Brief report
Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration
Raffaella Rosso 1,
Antonio Di Biagio 1 *,
Chiara Dentone 1,
Guido Castelli Gattinara 2,
Alessandra Maria Martino 2,
Alessandra Viganò 3,
Marzia Merlo 3,
Carlo Giaquinto 4,
Osvalda Rampon 4,
Matteo Bassetti 1,
Giorgio Gatti 1,
and
Claudio Viscoli 1
2 Bambin Gesù Children's Hospital, Rome, Italy
3 Department of Pediatrics, L. Sacco Hospital, Milan, Italy
4 Department of Pediatrics, University of Padua, Padua, Italy
Antonio Di Biagio, E-mail: antonio.dibiagio{at}hsanmartino.liguria.it
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. L. Robbins, E. V. Capparelli, E. G. Chadwick, R. Yogev, L. Serchuck, C. Worrell, M. E. Smith, C. Alvero, T. Fenton, B. Heckman, et al. Pharmacokinetics of High-Dose Lopinavir-Ritonavir with and without Saquinavir or Nonnucleoside Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus-Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3276 - 3283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Hammer, J. J. Eron Jr, P. Reiss, R. T. Schooley, M. A. Thompson, S. Walmsley, P. Cahn, M. A. Fischl, J. M. Gatell, M. S. Hirsch, et al. Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel JAMA, August 6, 2008; 300(5): 555 - 570. [Abstract] [Full Text] [PDF]
|
|